Inhibikase Therapeutics Inc (IKT)

04:58 AM

Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders - TipRanks

04:58 AM

Nov 14, 2024

Inhibikase Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 14, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Expands Stake in Inhibikase Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Inhibikase Therapeutics Inc (IKT) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Nov 14, 2024

Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c) - TipRanks

Nov 14, 2024

Nov 14, 2024

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - The Bakersfield Californian

Nov 14, 2024

Nov 14, 2024

Inhibikase Secures $275M Financing Deal, Advances PAH Drug Trial Despite Q3 Loss | IKT Stock News - StockTitan

Nov 14, 2024

Nov 08, 2024

Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential - Investing.com

Nov 08, 2024

Nov 08, 2024

Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential By Investing.com - Investing.com Canada

Nov 08, 2024

Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024

Oct 24, 2024

Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More - Insider Monkey

Oct 24, 2024

Oct 24, 2024

Director Arvind Kush Acquires 145,000 Shares of Inhibikase Thera - GuruFocus.com

Oct 24, 2024

Oct 23, 2024

Inhibikase therapeutics director Amit Munshi buys $500k in shares - Investing.com India

Oct 23, 2024

Oct 23, 2024

Inhibikase therapeutics director Amit Munshi buys $500k in shares By Investing.com - Investing.com Australia

Oct 23, 2024

Oct 23, 2024

Inhibikase Therapeutics director Bellini acquires $2m in stock - Investing.com India

Oct 23, 2024

Oct 23, 2024

Inhibikase Therapeutics director Bellini acquires $2m in stock By Investing.com - Investing.com South Africa

Oct 23, 2024

Oct 23, 2024

Inhibikase therapeutics director Kush Arvind buys $198,650 in stock - Investing.com

Oct 23, 2024

Oct 23, 2024

Inhibikase Therapeutics Secures Funding and Strengthens Leadership - Yahoo Finance

Oct 23, 2024

Oct 23, 2024

Inhibikase (IKT) Stock Climbs After-Market Following Key Financing - Stocks Telegraph

Oct 23, 2024

Oct 22, 2024

Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance

Oct 22, 2024

Oct 22, 2024

Perceptive Advisors LLC Acquires New Stake in Inhibikase Therape - GuruFocus.com

Oct 22, 2024

Oct 22, 2024

Inhibikase Therapeutics stock rises after pricing $110M private offering - MSN

Oct 22, 2024

Oct 21, 2024

IKTInhibikase Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 21, 2024

Oct 21, 2024

Inhibikase Therapeutics Announces Closing of up to $275 - GlobeNewswire

Oct 21, 2024

Oct 21, 2024

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - StockTitan

Oct 21, 2024

Oct 18, 2024

Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance

Oct 18, 2024

Oct 14, 2024

Inhibikase Therapeutics’ $110 Million Private Placement - Global Legal Chronicle

Oct 14, 2024

Oct 14, 2024

Analyzing the Impact of Earnings Reports on Inhibikase Therapeutics Inc Inc. (IKT) Price Performance - The InvestChronicle

Oct 14, 2024

Oct 14, 2024

500: Something went wrong - Investing.com

Oct 14, 2024

Oct 11, 2024

Inhibikase Therapeutics Secures $110M for Drug Development - Yahoo Finance

Oct 11, 2024

Oct 11, 2024

Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares - GuruFocus.com

Oct 11, 2024

Oct 11, 2024

Inhibikase Therapeutics Inc (IKT) expanding its growth trajectory ahead - SETE News

Oct 11, 2024

Oct 10, 2024

Inhibikase Therapeutics, Inc. Announces Pricing of $110 Million Private Placement - Marketscreener.com

Oct 10, 2024

Oct 10, 2024

Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline - Yahoo Finance

Oct 10, 2024

Oct 09, 2024

Inhibikase Therapeutics Inc. (NASDAQ:IKT) Stock Hits 5-Month High On Private Placement - DRP Journal

Oct 09, 2024

Oct 09, 2024

Inhibikase Therapeutics Inc’s Banking’s 100-Day Moving Average at 1.4198: Will the Stock Break Through? - The InvestChronicle

Oct 09, 2024

Oct 09, 2024

IKT’s price-to-free cash flow ratio: What it means for investors - US Post News

Oct 09, 2024

Oct 09, 2024

Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today - Benzinga

Oct 09, 2024

Oct 09, 2024

Inhibikase Therapeutics announces $110 million financing - Investing.com

Oct 09, 2024

Oct 09, 2024

Inhibikase Therapeutics Announces Pricing of $110 Million - GlobeNewswire

Oct 09, 2024

Oct 09, 2024

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension - Quantisnow

Oct 09, 2024

Sep 23, 2024

Fennec Pharmaceuticals (NASDAQ:FENC) & Inhibikase Therapeutics (NYSE:IKT) Head to Head Review - Defense World

Sep 23, 2024

Sep 20, 2024

Ieq Capital LLC Purchases 2,616 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat

Sep 20, 2024

Sep 19, 2024

Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors Australia

Sep 19, 2024

Sep 19, 2024

J.W. Cole Advisors Inc. Has $225,000 Holdings in InvenTrust Properties Corp. (NYSE:IVT) - Defense World

Sep 19, 2024

Sep 19, 2024

Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business - Yahoo Finance

Sep 19, 2024